Loading...
Loading...
ONCS| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 9,416.4K |
| Operating I/L | -9,416.4K |
| Other Income/Expense | -488.0K |
| Interest Income | 0.0K |
| Pretax | -9,904.5K |
| Income Tax Expense | 3.0K |
| Net Income/Loss | -9,907.4K |
OncoSec Medical Incorporated is a late-stage immuno-oncology company specializing in intra-tumoral DNA-based therapeutics for cancer treatment. Its lead product candidate, ImmunoPulse IL-12, utilizes an electroporation device to deliver DNA-encoded interleukin-12, aiming to stimulate anti-tumor immune responses. The company is focused on developing combination therapies with KEYTRUDA for advanced melanoma and metastatic triple negative breast cancer, as well as monotherapy for metastatic melanoma and advanced or metastatic TNBC. OncoSec has clinical trial collaborations with Merck & Co., Inc. and research collaborations with Duke University and Roswell Park Comprehensive Cancer Center to evaluate its technologies. The company generates revenue through the development and commercialization of its innovative cancer treatment solutions.
